Search Results - "Mastim, Mushtaque"
-
1
Single-Center Investigation of the Pharmacokinetics of WCK 4282 (Cefepime-Tazobactam Combination) in Renal Impairment
Published in Antimicrobial agents and chemotherapy (01-10-2019)“…WCK 4282 is a combination product of cefepime (FEP) and tazobactam (TAZ) in a 1:1 ratio currently under development for the treatment of multidrug-resistant…”
Get full text
Journal Article -
2
Correction to: Comparative evaluation of pharmacokinetics and pharmacodynamics of insulin glargine (Glaritus®) and Lantus® in healthy subjects: a double-blind, randomized clamp study
Published in Acta diabetologica (2021)“…Authors would like to correct the error in table 2 of the online published article…”
Get full text
Journal Article -
3
A Prospective Multicenter Study to Evaluate the Safety and Efficacy of the Topical Application of MYOWNN™, an Autologous Growth Factor Concentrate (AGFC) Serum, in Anti-Aging
Published in Curēus (Palo Alto, CA) (21-05-2022)“…BackgroundGrowth factors from platelets have been emerging as a revolutionary treatment with the ability to induce cell growth in the skin, which results in…”
Get full text
Journal Article -
4
Single-Center Evaluation of the Pharmacokinetics of WCK 5222 (Cefepime-Zidebactam Combination) in Subjects with Renal Impairment
Published in Antimicrobial agents and chemotherapy (01-01-2019)“…WCK 5222 is a novel β-lactam-β-lactam-enhancer combination of cefepime (FEP) and zidebactam (ZID). ZID is a novel β-lactam enhancer with a dual action of…”
Get full text
Journal Article -
5
Comparative evaluation of pharmacokinetics and pharmacodynamics of insulin glargine (Glaritus®) and Lantus® in healthy subjects: a double-blind, randomized clamp study
Published in Acta diabetologica (01-05-2018)“…Aims The objective of the study was to compare the pharmacokinetic (PK) and pharmacodynamic (PD) properties of an insulin glargine formulation, Glaritus ®…”
Get full text
Journal Article -
6
An Open-Labeled Randomized Prospective Multi-center Study to Evaluate the Efficacy and Safety of Intra-articular Injection of OSSINEXT™, an Autologous Growth Factor Concentrate (AGFC) Compared to Hyaluronic Acid (HA) in Knee Osteoarthritis
Published in Curēus (Palo Alto, CA) (03-11-2022)“…Osteoarthritis (OA) is known as degenerative arthritis and is the second most common rheumatologic problem with a prevalence of 22%-39% in India. Knee OA (KOA)…”
Get full text
Journal Article